Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

Yıl: 2021 Cilt: 32 Sayı: 2 Sayfa Aralığı: 155 - 163 Metin Dili: İngilizce DOI: 10.5152/tjg.2020.19569 İndeks Tarihi: 31-05-2022

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?

Öz:
Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. World Health Organization. Guidelines for the Screening Care and Treatment of Persons with Hepatitis C Infection. Geneva: WHO; 2014.
  • 2. World Health Organization. Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Geneva: WHO; 2018.
  • 3. Gürbüz Y, Tülek NE, Tütüncü EE, et al. Evaluation of dual therapy in real life setting in treatment-naive Turkish patients with HCV infection: a multicenter, retrospective study. Balk Med J. 2016;33(1):18-26. [CrossRef]
  • 4. Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 2015;7(12):6716-6729. [CrossRef]
  • 5. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Eng J Med. 2014;370(16):1483-1493. [CrossRef]
  • 6. Buti M, Riveiro-Barciela M, Esteban R. Management of directacting antiviral agent failures. J Hepatol. 2015;63(6):1511-1522. [CrossRef]
  • 7. Crespo J, Calleja JL, Fernández I, et al. Real-world effectiveness and safety of oral combination antiviral therapy for hepatitis C virus genotype 4 infection. Clin Gastroenterol Hepatol. 2017;15(6):945. e1-949.e1. [CrossRef]
  • 8. Tapper EB, Bacon BR, Curry MP, et al. Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health Study. J Viral Hepat. 2017;24(1):22-27. [CrossRef]
  • 9. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199- 236. [CrossRef]
  • 10. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2017;66:152-194.
  • 11. Aygen B, Demirtürk N, Türker N, et al. Management of chronic hepatitis C virus infection: a consensus report of the study group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Disease-2017 Update. KLİMİK J. 2017;30(1)(Suppl 1):2-36. [CrossRef]
  • 12. European Association for the Study of the Liver, European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511. [CrossRef]
  • 13. Tao T, Jiang X, Chen Y, Song Y. Efficacy and safety of ledipasvir/ sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: a meta-analysis. Int J Infcet Dis. 2017;55:56-71. [CrossRef]
  • 14. Calleja JL, Crespo J, Rincón D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol. 2017;66(6):1138-1148. [CrossRef]
  • 15. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naïve genotype 1 hepatitis C infected patients. Hepatology. 2016;64(2):405- 414. [CrossRef]
  • 16. Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Palecki J, Reddy KR. Sofosbuvir-ledpasvir with or without ribavirin for chronic hepatitis C genotypes 1 and 6: real-world experience in Vietnam. Antivir Ther. 2018;23(5):415-423. [CrossRef]
  • 17. Stokes W, Fenton C, Clement F, et al. The efficacy and safety of 12 weeks of sofosbuvir and ledipasvir versus sofosbuvir, ledipasvir, and ribavirin in patients with chronic hepatitis C, genotype 1, who have cirrhosis and have failed prior therapy: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2017;2017:6468309. [CrossRef]
  • 18. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a-proof-of-concept, single-center, openlabel phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049- 1054. [CrossRef]
  • 19. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Hepatology. 2012;56(Suppl):306A-307A.
  • 20. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Eng J Med. 2013;368(20):1867-1877. [CrossRef]
  • 21. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Eng J Med. 2014;370(21):1993-2001. [CrossRef]
  • 22. Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatmennaiv and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat. 2016;23(5):358-365. [CrossRef]
  • 23. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762-768. [CrossRef]
  • 24. Han SY, Woo HY, Heo J, et al. The predictors of sustained virological response with sofosbuvir and ribavirin in patients with cronic hepatitis C genotype 2. Korean J Intern Med. 2019 Mar 19. [CrossRef] Online ahead of print.
  • 25. Gayam V, Tiongson B, Khalid M, et al. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African- American patients: a community-based retrospective cohort study. Eur J Gastroenterol Hepatol. 2018;30(10):1200-1207. [CrossRef]
  • 26. Lim JK, Liapakis AM, Shiffman ML, et al. Safety and effectiveness of ledipasvir and sofosbuvir with or without ribavirin in treatmentexperienced patients with genotype 1 hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2018;16(11):1811.e4-1819.e4. [CrossRef]
APA Demirturk N, AYGEN B, Çelik İ, mıstık r, AKHAN S, Barut S, Ural O, Batirel A, SİMSEK F, ERSÖZ G, İNAN D, KINIKLI S, Turker N, Bilgin H, Gürbüz Y, Tulek N, TARAKÇI H, YILDIZ O, Türkoğlu Yılmaz E, GÜZEL D, ŞİMŞEK S, TUNA N, Aktug Demir N, ÇAGATAY A, Cetinkaya R, karakeçili f, Hakyemez I, Tuncer Ertem G, ÖRMEN B, korkmaz p, SİLİ U, Kuruüzüm Z, ŞENER A, ÖZEL S, Öztürk S, süer k, CELEN M, konya p, ASAN A, SALTOĞLU N, Doğan N (2021). Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. , 155 - 163. 10.5152/tjg.2020.19569
Chicago Demirturk Nese,AYGEN Bilgehan,Çelik İlhami,mıstık reşit,AKHAN Sıla,Barut Sener,Ural Onur,Batirel Ayse,SİMSEK FUNDA,ERSÖZ Gülden,İNAN DİLARA,KINIKLI SAMI,Turker Nesrin,Bilgin Huseyin,Gürbüz Yunus,Tulek Necla,TARAKÇI Hüseyin,YILDIZ Orhan,Türkoğlu Yılmaz Emine,GÜZEL Deniz KOMALAK,ŞİMŞEK Sümeyra,TUNA Nazan,Aktug Demir Nazlim,ÇAGATAY ARIF ATAHAN,Cetinkaya Riza Aytac,karakeçili faruk,Hakyemez Ismail Necati,Tuncer Ertem Gunay,ÖRMEN Bahar,korkmaz pınar,SİLİ Uluhan,Kuruüzüm Ziya,ŞENER Alper,ÖZEL Selcan ARSLAN,Öztürk Sinan,süer kaya,CELEN MUSTAFA,konya petek,ASAN Ali,SALTOĞLU Neşe,Doğan Nurhan Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. (2021): 155 - 163. 10.5152/tjg.2020.19569
MLA Demirturk Nese,AYGEN Bilgehan,Çelik İlhami,mıstık reşit,AKHAN Sıla,Barut Sener,Ural Onur,Batirel Ayse,SİMSEK FUNDA,ERSÖZ Gülden,İNAN DİLARA,KINIKLI SAMI,Turker Nesrin,Bilgin Huseyin,Gürbüz Yunus,Tulek Necla,TARAKÇI Hüseyin,YILDIZ Orhan,Türkoğlu Yılmaz Emine,GÜZEL Deniz KOMALAK,ŞİMŞEK Sümeyra,TUNA Nazan,Aktug Demir Nazlim,ÇAGATAY ARIF ATAHAN,Cetinkaya Riza Aytac,karakeçili faruk,Hakyemez Ismail Necati,Tuncer Ertem Gunay,ÖRMEN Bahar,korkmaz pınar,SİLİ Uluhan,Kuruüzüm Ziya,ŞENER Alper,ÖZEL Selcan ARSLAN,Öztürk Sinan,süer kaya,CELEN MUSTAFA,konya petek,ASAN Ali,SALTOĞLU Neşe,Doğan Nurhan Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. , 2021, ss.155 - 163. 10.5152/tjg.2020.19569
AMA Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. . 2021; 155 - 163. 10.5152/tjg.2020.19569
Vancouver Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. . 2021; 155 - 163. 10.5152/tjg.2020.19569
IEEE Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N "Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?." , ss.155 - 163, 2021. 10.5152/tjg.2020.19569
ISNAD Demirturk, Nese vd. "Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?". (2021), 155-163. https://doi.org/10.5152/tjg.2020.19569
APA Demirturk N, AYGEN B, Çelik İ, mıstık r, AKHAN S, Barut S, Ural O, Batirel A, SİMSEK F, ERSÖZ G, İNAN D, KINIKLI S, Turker N, Bilgin H, Gürbüz Y, Tulek N, TARAKÇI H, YILDIZ O, Türkoğlu Yılmaz E, GÜZEL D, ŞİMŞEK S, TUNA N, Aktug Demir N, ÇAGATAY A, Cetinkaya R, karakeçili f, Hakyemez I, Tuncer Ertem G, ÖRMEN B, korkmaz p, SİLİ U, Kuruüzüm Z, ŞENER A, ÖZEL S, Öztürk S, süer k, CELEN M, konya p, ASAN A, SALTOĞLU N, Doğan N (2021). Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. Turkish Journal of Gastroenterology, 32(2), 155 - 163. 10.5152/tjg.2020.19569
Chicago Demirturk Nese,AYGEN Bilgehan,Çelik İlhami,mıstık reşit,AKHAN Sıla,Barut Sener,Ural Onur,Batirel Ayse,SİMSEK FUNDA,ERSÖZ Gülden,İNAN DİLARA,KINIKLI SAMI,Turker Nesrin,Bilgin Huseyin,Gürbüz Yunus,Tulek Necla,TARAKÇI Hüseyin,YILDIZ Orhan,Türkoğlu Yılmaz Emine,GÜZEL Deniz KOMALAK,ŞİMŞEK Sümeyra,TUNA Nazan,Aktug Demir Nazlim,ÇAGATAY ARIF ATAHAN,Cetinkaya Riza Aytac,karakeçili faruk,Hakyemez Ismail Necati,Tuncer Ertem Gunay,ÖRMEN Bahar,korkmaz pınar,SİLİ Uluhan,Kuruüzüm Ziya,ŞENER Alper,ÖZEL Selcan ARSLAN,Öztürk Sinan,süer kaya,CELEN MUSTAFA,konya petek,ASAN Ali,SALTOĞLU Neşe,Doğan Nurhan Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. Turkish Journal of Gastroenterology 32, no.2 (2021): 155 - 163. 10.5152/tjg.2020.19569
MLA Demirturk Nese,AYGEN Bilgehan,Çelik İlhami,mıstık reşit,AKHAN Sıla,Barut Sener,Ural Onur,Batirel Ayse,SİMSEK FUNDA,ERSÖZ Gülden,İNAN DİLARA,KINIKLI SAMI,Turker Nesrin,Bilgin Huseyin,Gürbüz Yunus,Tulek Necla,TARAKÇI Hüseyin,YILDIZ Orhan,Türkoğlu Yılmaz Emine,GÜZEL Deniz KOMALAK,ŞİMŞEK Sümeyra,TUNA Nazan,Aktug Demir Nazlim,ÇAGATAY ARIF ATAHAN,Cetinkaya Riza Aytac,karakeçili faruk,Hakyemez Ismail Necati,Tuncer Ertem Gunay,ÖRMEN Bahar,korkmaz pınar,SİLİ Uluhan,Kuruüzüm Ziya,ŞENER Alper,ÖZEL Selcan ARSLAN,Öztürk Sinan,süer kaya,CELEN MUSTAFA,konya petek,ASAN Ali,SALTOĞLU Neşe,Doğan Nurhan Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. Turkish Journal of Gastroenterology, vol.32, no.2, 2021, ss.155 - 163. 10.5152/tjg.2020.19569
AMA Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. Turkish Journal of Gastroenterology. 2021; 32(2): 155 - 163. 10.5152/tjg.2020.19569
Vancouver Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?. Turkish Journal of Gastroenterology. 2021; 32(2): 155 - 163. 10.5152/tjg.2020.19569
IEEE Demirturk N,AYGEN B,Çelik İ,mıstık r,AKHAN S,Barut S,Ural O,Batirel A,SİMSEK F,ERSÖZ G,İNAN D,KINIKLI S,Turker N,Bilgin H,Gürbüz Y,Tulek N,TARAKÇI H,YILDIZ O,Türkoğlu Yılmaz E,GÜZEL D,ŞİMŞEK S,TUNA N,Aktug Demir N,ÇAGATAY A,Cetinkaya R,karakeçili f,Hakyemez I,Tuncer Ertem G,ÖRMEN B,korkmaz p,SİLİ U,Kuruüzüm Z,ŞENER A,ÖZEL S,Öztürk S,süer k,CELEN M,konya p,ASAN A,SALTOĞLU N,Doğan N "Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?." Turkish Journal of Gastroenterology, 32, ss.155 - 163, 2021. 10.5152/tjg.2020.19569
ISNAD Demirturk, Nese vd. "Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?". Turkish Journal of Gastroenterology 32/2 (2021), 155-163. https://doi.org/10.5152/tjg.2020.19569